|
ニシナカ トモヒロ
Tomohiro Nishinaka
西中 知博 所属 医学部 医学科（東京女子医科大学病院） 職種 客員教授 |
|
| 論文種別 | その他 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Japanese registry for Mechanically Assisted Circulatory Support: First report. |
| 掲載誌名 | 正式名：The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 略 称：J Heart Lung Transplant ISSNコード：1053-2498/1557-3117 |
| 掲載区分 | 国外 |
| 出版社 | Elsevier B.V. |
| 巻・号・頁 | 36(10),pp.1087-1096 |
| 著者・共著者 | Nakatani Takeshi, Sase Kazuhiro, Oshiyama Hiroaki, Akiyama Masatoshi, Horie Masao, Nawata Kan, Nishinaka Tomohiro, Tanoue Yoshihisa, Toda Koichi, Tozawa Masao, Yamazaki Shunichi, Yanase Masanobu, Ohtsu Hiroshi, Ishida Michiko, Hiramatsu Ayaka, Ishii Kensuke, Kitamura Soichiro, |
| 発行年月 | 2017/10 |
| 概要 | BACKGROUND:
In Japan, ventricular assist devices (VADs) have been used for patients with severe heart failure as a bridge to transplantation (BTT) since 1992. However, it was not until 1997, when the Organ Transplant Law was enacted, that medical devices received approval by the national health insurance system for that use. To encourage research and development of innovative medical devices, the Pharmaceuticals and Medical Devices Agency has established a public-private partnership in collaboration with academic societies, hospitals and manufacturers. METHODS: The Japanese registry for Mechanically Assisted Circulatory Support (J-MACS) is a prospective registry designed to be harmonized with the Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS). Participation in J-MACS is mandatory for device manufacturers to meet the conditions of approval as well as for hospitals to obtain authorization for reimbursement from the national health insurance system. RESULTS: From June 2010 to April 2015, 476 patients were registered at 31 hospitals. Of these, analysis of primary VAD patients (n = 332) revealed that their overall 360-day survival was 91% (implantable 93%, extracorporeal 84%). CONCLUSIONS: This initial report from J-MACS focuses on patients' demographics, device types, survival, competing outcomes, adverse events and successful examples of system failure detection. |
| DOI | 10.1016/j.healun.2017.08.002 |
| PMID | 28942783 |